Partial
Partially Aligned
Patient Risk:
Moderate
Summary
Only a small subset of the provided claims can be evaluated against the supplied label excerpts (contraindication and thyroid C-cell tumor warning). Most claims (indications, dosing, trial outcomes, packaging/NDC, side effects, drug comparisons, and detailed pharmacology) are not supported or contradicted by the supplied label text, creating major coverage gaps.
Category Scores
Accurate Statements
Saxenda is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
Supported by provided label excerpts in SECTION 4 CONTRAINDICATIONS and SECTION 5.1 Risk of Thyroid C-cell Tumors.
Saxenda's active ingredient is liraglutide.
Implied throughout the provided label excerpt text (risk section refers to 'liraglutide causes...'; product referenced as SAXENDA).
Unsupported Statements
Saxenda is a prescription medication used for chronic weight management in adults with a body mass index (BMI) of 30 or greater, or a BMI of 27 or greater with at least one weight-related condition.
No indication text is included in the supplied label excerpts.
Each Saxenda pen contains 3 mL of solution.
No concentration/volume or pen fill volume is included in the supplied label excerpts.
Saxenda is typically packaged in a box of five pens.
No packaging configuration is included in the supplied label excerpts.
The NDC for a package of 5 Saxenda pens, each containing 18 mg of the drug in 3 mL, is 55513-001-05.
No NDC information is included in the supplied label excerpts.
Saxenda is administered as a subcutaneous injection.
No administration route instructions are included in the supplied label excerpts.
Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist.
No mechanism-of-action description is included in the supplied label excerpts.
Liraglutide mimics the GLP-1 hormone to help regulate appetite and food intake.
No appetite/food intake MOA text is included in the supplied label excerpts.
Liraglutide slows down gastric emptying, leading to a feeling of fullness.
No gastric emptying/fullness MOA text is included in the supplied label excerpts.
Liraglutide acts on brain receptors to reduce hunger and increase satiety.
No brain receptor/satiety MOA text is included in the supplied label excerpts.
Some patents for liraglutide have expiration dates extending into the future, with some general patents expiring around 2028 and others expiring later.
No patent-expiration or litigation/IP timing information is included in the supplied label excerpts.
Generic versions of Saxenda, known as biosimilars in the case of injectable biologics, are contingent upon patent expirations and regulatory approval.
No patent/regulatory pathway timing details are included in the supplied label excerpts.
Companies may seek to develop and market generic alternatives once key patents protecting liraglutide and its specific uses expire.
No patent/prospective development statements are included in the supplied label excerpts.
The regulatory pathway for biosimilars is rigorous and requires demonstration of similarity in terms of safety, efficacy, and quality to the reference product, Saxenda.
No biosimilar regulatory pathway description is included in the supplied label excerpts.
The most common side effects of Saxenda include nausea, diarrhea, constipation, vomiting, and decreased appetite.
No adverse reaction frequency list is included in the supplied label excerpts.
Gastrointestinal side effects are often more pronounced when starting Saxenda or increasing the dose.
No dose-related adverse effect pattern is included in the supplied label excerpts.
For many individuals, gastrointestinal side effects tend to lessen over time.
No adverse reaction trajectory text is included in the supplied label excerpts.
Serious side effects of Saxenda can include pancreatitis, gallbladder problems, kidney problems, and an increased heart rate.
No serious adverse reaction list is included in the supplied label excerpts.
Saxenda is administered as a once-daily subcutaneous injection.
No dosing regimen or frequency instructions are included in the supplied label excerpts.
The typical starting dose of Saxenda is 0.6 mg once daily.
No dosing regimen text is included in the supplied label excerpts.
Saxenda is increased gradually over five weeks to a maintenance dose of 3.0 mg once daily.
No titration schedule text is included in the supplied label excerpts.
The titration schedule helps patients tolerate the medication and minimize gastrointestinal side effects.
No rationale for titration or GI side-effect mitigation text is included in the supplied label excerpts.
Clinical trials for Saxenda have demonstrated its effectiveness in promoting weight loss and improving weight-related health outcomes.
No clinical trial/efficacy summary is included in the supplied label excerpts.
In the SCALE trial, adults treated with Saxenda achieved statistically significant reductions in body weight compared to placebo.
No SCALE trial efficacy results are included in the supplied label excerpts.
In the SCALE trial, a substantial percentage of participants treated with Saxenda reached at least 5% weight loss.
No SCALE trial responder proportion data is included in the supplied label excerpts.
Saxenda data indicated improvements in cardiometabolic risk factors.
No cardiometabolic outcomes are included in the supplied label excerpts.
Saxenda is approved for chronic weight management.
No approval/indication text is included in the supplied label excerpts.
Victoza and Saxenda both contain liraglutide as their active ingredient.
No Victoza comparison content is included in the supplied label excerpts.
Victoza is approved for improving glycemic control in adults with type 2 diabetes mellitus.
No Victoza label content is included in the supplied label excerpts.
Victoza is approved for reducing the risk of major cardiovascular events in adults with type 2 diabetes mellitus and established cardiovascular disease.
No Victoza label content is included in the supplied label excerpts.
Saxenda is administered at a higher dose (up to 3.0 mg once daily) compared to Victoza (up to 1.8 mg once daily).
No dosing comparison text is included in the supplied label excerpts.
Contradictions
Important Omissions
FDA-label sections covering Indications and Usage, Dosage and Administration (including titration and frequency), Contraindications full context, and Adverse Reactions details beyond thyroid C-cell tumors.
Importance:
High
Safety Assessment
Potential Patient Risk:
Moderate
The label excerpt provided supports the thyroid C-cell tumor warning and the contraindication (MTC/MEN 2). However, many other statements about dosing, administration, common/serious adverse reactions, and efficacy are not supported by the provided label text, which could mislead users about safe use or risk profile if treated as label-accurate.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Most claims are not verifiable against the limited supplied FDA label excerpts; only the MTC/MEN 2 contraindication and thyroid C-cell tumor warning are supported.
Suggested Improvement
Evaluate and present only claims that are explicitly supported by the provided label sections (4, 5.1, 6, 13.1, 17) or supply the missing label sections (Indications, Dosage/Administration, Adverse Reactions, etc.) needed to substantiate the other claims.